Can a smartwatch help control a common heart rhythm problem?
NCT ID NCT07445789
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two common heart rate-lowering drugs, verapamil and metoprolol, in 436 adults with paroxysmal atrial fibrillation (AF). It also tests whether using a smartwatch for self-care can reduce hospital visits and improve symptoms. The goal is to find better ways to manage AF and avoid emergency care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- verapamil or metoprolol
- What this could lead to
- If successful, this could show that verapamil or smartwatch-guided self-care reduces hospital visits and improves quality of life for people with paroxysmal atrial fibrillation.
- What could go wrong
- This is a phase 4 trial, so both drugs are already approved, but results may not apply to all AF patients. The smartwatch component depends on patient engagement and may not show clear benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a smartphone alert replace daily blood thinners for AF?
- Blood fat clues could flag hidden heart rhythm risk
- Could a bigger balloon tame the Heart's electrical chaos?
- Can a new heart ablation technique work without x-rays?
- Which blood thinner is safer for heart patients? a Head-to-Head test
- Smartphone light sensor may spot when an irregular heartbeat fixes itself